Richard G Arms1, Charlotte C Sun2, Jennifer K Burzawa2, Nicole D Fleming2, Alpa M Nick2, Vijayashri Rallapalli2, Shannon N Westin2, Larissa A Meyer2, Pedro T Ramirez2, Pamela T Soliman3. 1. Department of Obstetrics and Gynecology, Creighton University Medical Center, Omaha, NE 68131, United States. 2. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. 3. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Electronic address: psoliman@mdanderson.org.
Abstract
BACKGROUND: There are well-described benefits to minimally invasive surgery including decreased blood loss, shorter hospital-stay, and faster recovery. The role of robotic surgery in gynecologic oncology has become increasingly prominent; however limited data are available on quality of life (QOL) after robotic surgery. METHODS: In this prospective, IRB-approved study, women scheduled for robotic surgery for a gynecologic indication between May 2008 and February 2012 completed validated QOL measures at baseline, 6 weeks (6wk), and 4 months postoperative (4mo). Functional status (SF-12), symptom severity and interference (MDASI), sexual function (FSFI), and satisfaction with decision (SWD) were assessed at relevant time points. Differences between groups were evaluated using the Mann-Whitney test. RESULTS: Among 408 women who underwent robotic surgery 278 (68%) completed the QOL measures. Median age was 55.6 years (range 25.7-85.1). Median BMI was 31.3kg/m(2). The majority of patients were white (75%). The most common indication for surgery was endometrial cancer/hyperplasia (59.7%). While physical functioning declined from baseline to 6wk (51.4 to 41.6, p<0.001), it improved by 4mo (53.5). Mental functioning improved over time (baseline 48.6, 6wk 52.8, and 4mo 55.6, p<0.001). Symptom severity decreased over time (p<0.001) as did symptom interference (p<0.001). Sexual function improved significantly from baseline (8.6) to 4mo (20.2, p<0.001). Patients were satisfied with their decision making (SWD=30). CONCLUSION: In this prospective study, general health, symptom burden and sexual function returned to or improved beyond baseline levels within 6 weeks of surgery. Overall, women were satisfied with their decision to undergo robotic surgery.
BACKGROUND: There are well-described benefits to minimally invasive surgery including decreased blood loss, shorter hospital-stay, and faster recovery. The role of robotic surgery in gynecologic oncology has become increasingly prominent; however limited data are available on quality of life (QOL) after robotic surgery. METHODS: In this prospective, IRB-approved study, women scheduled for robotic surgery for a gynecologic indication between May 2008 and February 2012 completed validated QOL measures at baseline, 6 weeks (6wk), and 4 months postoperative (4mo). Functional status (SF-12), symptom severity and interference (MDASI), sexual function (FSFI), and satisfaction with decision (SWD) were assessed at relevant time points. Differences between groups were evaluated using the Mann-Whitney test. RESULTS: Among 408 women who underwent robotic surgery 278 (68%) completed the QOL measures. Median age was 55.6 years (range 25.7-85.1). Median BMI was 31.3kg/m(2). The majority of patients were white (75%). The most common indication for surgery was endometrial cancer/hyperplasia (59.7%). While physical functioning declined from baseline to 6wk (51.4 to 41.6, p<0.001), it improved by 4mo (53.5). Mental functioning improved over time (baseline 48.6, 6wk 52.8, and 4mo 55.6, p<0.001). Symptom severity decreased over time (p<0.001) as did symptom interference (p<0.001). Sexual function improved significantly from baseline (8.6) to 4mo (20.2, p<0.001). Patients were satisfied with their decision making (SWD=30). CONCLUSION: In this prospective study, general health, symptom burden and sexual function returned to or improved beyond baseline levels within 6 weeks of surgery. Overall, women were satisfied with their decision to undergo robotic surgery.
Authors: Marie Fidela R Paraiso; Beri Ridgeway; Amy J Park; J Eric Jelovsek; Matthew D Barber; Tommaso Falcone; Jon I Einarsson Journal: Am J Obstet Gynecol Date: 2013-02-08 Impact factor: 8.661
Authors: Pamela T Soliman; Ginger Langley; Mark F Munsell; Hemang A Vaniya; Michael Frumovitz; Pedro T Ramirez Journal: Ann Surg Oncol Date: 2012-10-05 Impact factor: 5.344
Authors: Theodoor E Nieboer; Jan C M Hendriks; Marlies Y Bongers; Mark E Vierhout; Kirsten B Kluivers Journal: Obstet Gynecol Date: 2012-01 Impact factor: 7.661
Authors: Pamela T Soliman; Michael Frumovitz; Charlotte C Sun; Ricardo Dos Reis; Kathleen M Schmeler; Alpa M Nick; Shannon N Westin; Jubilee Brown; Charles F Levenback; Pedro T Ramirez Journal: Gynecol Oncol Date: 2011-08-27 Impact factor: 5.482
Authors: Monika Janda; Val Gebski; Alison Brand; Russel Hogg; Thomas W Jobling; Russel Land; Tom Manolitsas; Anthony McCartney; Marcelo Nascimento; Deborah Neesham; James L Nicklin; Martin K Oehler; Geoff Otton; Lewis Perrin; Stuart Salfinger; Ian Hammond; Yee Leung; Tom Walsh; Peter Sykes; Hextan Ngan; Andrea Garrett; Michael Laney; Tong Yow Ng; Karfai Tam; Karen Chan; C David H Wrede; Selvan Pather; Bryony Simcock; Rhonda Farrell; Andreas Obermair Journal: Lancet Oncol Date: 2010-07-16 Impact factor: 41.316
Authors: Jason D Wright; Cande V Ananth; Sharyn N Lewin; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: Alice B Kornblith; Helen Q Huang; Joan L Walker; Nick M Spirtos; Jacob Rotmensch; David Cella Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Georgios Gitas; I Alkatout; L Proppe; L Hanker; L Allahqoli; G Grimbizis; A Rody; N Werner; S Sommer; S Baum Journal: Arch Gynecol Obstet Date: 2021-12-26 Impact factor: 2.493